Cargando…
Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
PURPOSE: The benefit of adjuvant chemotherapy following curative-intent surgery in pancreatic ductal adenocarcinoma (PDAC) patients who had received neoadjuvant FOLFIRINOX is unclear. This study aimed to assess the survival benefit of adjuvant chemotherapy in this patient population. MATERIALS AND M...
Autores principales: | Lee, So Heun, Hwang, Dae Wook, Yoo, Changhoon, Kim, Kyu-pyo, Kang, Sora, Jeong, Jae Ho, Oh, Dongwook, Song, Tae Jun, Lee, Sang Soo, Park, Do Hyun, Seo, Dong Wan, Park, Jin-hong, Song, Ki Byung, Lee, Jae Hoon, Lee, Woohyung, Park, Yejong, Kwak, Bong Jun, Chang, Heung-Moon, Ryoo, Baek-Yeol, Kim, Song Cheol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372602/ https://www.ncbi.nlm.nih.gov/pubmed/36915253 http://dx.doi.org/10.4143/crt.2022.409 |
Ejemplares similares
-
Real-world outcomes of adjuvant gemcitabine versus
gemcitabine plus capecitabine for resected pancreatic ductal
adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022) -
FOLFIRINOX in borderline resectable and locally advanced unresectable
pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020) -
Usefulness of Inflammation-Based Prognostic Scores in Patients with Surgically Treated Pancreatic Ductal Adenocarcinoma
por: Hong, Sarang, et al.
Publicado: (2021) -
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
por: Yoo, Changhoon, et al.
Publicado: (2017) -
Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer
por: Lee, Woohyung, et al.
Publicado: (2020)